339 related articles for article (PubMed ID: 18070221)
1. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
Bijl MJ; Visser LE; Hofman A; Vulto AG; van Gelder T; Stricker BH; van Schaik RH
Br J Clin Pharmacol; 2008 Apr; 65(4):558-64. PubMed ID: 18070221
[TBL] [Abstract][Full Text] [Related]
2. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.
Kwadijk-de Gijsel S; Bijl MJ; Visser LE; van Schaik RH; Hofman A; Vulto AG; van Gelder T; Ch Stricker BH
Br J Clin Pharmacol; 2009 Aug; 68(2):221-5. PubMed ID: 19694742
[TBL] [Abstract][Full Text] [Related]
3. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
4. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
8. Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.
Frederiksen T; Smith RL; Jukic MM; Molden E
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):396-399. PubMed ID: 35703273
[TBL] [Abstract][Full Text] [Related]
9. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
[TBL] [Abstract][Full Text] [Related]
10. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
11. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ
J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
[TBL] [Abstract][Full Text] [Related]
12. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
Lindskov Krog P; Osterberg O; Gundorf Drewes P; Rembratt Å; Schultz A; Timmer W
Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
[TBL] [Abstract][Full Text] [Related]
14. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Zawertailo LA; Kaplan HL; Busto UE; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
[TBL] [Abstract][Full Text] [Related]
15. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
[TBL] [Abstract][Full Text] [Related]
17. Managing rapid metabolizers of antidepressants.
Kraus RP; Diaz P; McEachran A
Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
[TBL] [Abstract][Full Text] [Related]
18. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]